The intent of this study is to evaluate the efficacy, safety, and tolerability of BI 1291583 2.5 mg q.d. compared to placebo in participants with bronchiectasis independent of underlying etiologies. The ability of BI 1291583 2.5 mg in reducing the number of pulmonary exacerbations over a treatment period of at least 52 weeks and up to 76 weeks along with a favourable benefit-risk ratio in patients with bronchiectasis will be investigated.
